Correlation between biomarkers of exposure, effect and potential harm in the urine of electronic cigarette users

BMJ Open Respiratory Research

Volumn 7, Issue 1, 2020, Pages

  Sakamaki Ching, Shane ^a   Williams, Monique ^a   Hua, My ^a   Li, Jun ^a   Bates, Steve M ^a   Robinson, Andrew N ^a   Lyons, Timothy W ^a   Goniewicz, MacIej Lukasz ^b   Talbot, Prue ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

biomarkers; cigarettes; electronic cigarettes; metals; non smokers

Indexed keywords

BIOLOGICAL MARKER; CADMIUM; CHROMIUM; COTININE; CREATININE; METALLOTHIONEIN; NICKEL; REACTIVE OXYGEN METABOLITE; SELENIUM; ZINC; METAL;

ADULT; AGED; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA DAMAGE; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXIDATIVE STRESS; PRIORITY JOURNAL; SMOKING; URINALYSIS; VAPING; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; EXPOSURE; STATISTICAL MODEL; URINE; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; COTININE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INHALATION EXPOSURE; LINEAR MODELS; MALE; METALS; MIDDLE AGED; VAPING; YOUNG ADULT;

EID: 85079752975     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2019-000452     Document Type: Article

References (58)

1. U. S. Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress. A Report of the Surgeon General. Atlanta: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2011. United States Surgeon General. The Health Consequences of Smoking-50 Years of progress: A Report of the Surgeon General: 510072014-001, 2014.
2. U. S. Department of Health and Human Services. E-Cigarette use among youth and young adults. A report of the surgeon General. Atlanta, GA: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2016.
3. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2014;23:133-9.
4. Behar RZ, Davis B, Wang Y, et al. Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicology in Vitro 2014;28:198-208.
5. Behar RZ, Luo W, Lin SC, et al. Distribution, quantification and toxicity of cinnamaldehyde in electronic cigarette refill fluids and aerosols. Tob Control 2016;25:ii94-102.
6. Williams M, Villarreal A, Bozhilov K, et al. Metal and silicate particles including nanoparticles are present in electronic cigarette Cartomizer fluid and aerosol. PLoS One 2013;8:e57987.
7. Williams M, Bozhilov K, Ghai S, et al. Elements including metals in the atomizer and aerosol of disposable electronic cigarettes and electronic hookahs. PLoS One 2017;12:e0175430.
8. Goel R, Durand E, Trushin N, et al. Highly reactive free radicals in electronic cigarette aerosols. Chem Res Toxicol 2015;28:1675-7.
9. Bahl V, Lin S, Xu N, et al. Comparison of electronic cigarette refill fluid cytotoxicity using embryonic and adult models. Reprod Toxicol 2012;34:529-37.
10. Behar RZ, Wang Y, Talbot P. Comparing the cytotoxicity of electronic cigarette fluids, aerosols and solvents. Tob Control 2018;27:325-33.
11. Scott A, Lugg ST, Aldridge K, et al. Pro-Inflammatory effects of e-cigarette vapour condensate on human alveolar macrophages. Thorax 2018;73:1161-9.
12. Hua M, Talbot P. Potential health effects of electronic cigarettes: a systematic review of case reports. Prev Med Rep 2016;4:169-78.
13. Moheimani RS, Bhetraratana M, Yin F, et al. Increased cardiac sympathetic activity and oxidative stress in habitual electronic cigarette users: implications for cardiovascular risk. JAMA Cardiol 2017;2:278-84.
14. Fracol M, Dorfman R, Janes L, et al. The surgical impact of e-cigarettes: a case report and review of the current literature. Arch Plast Surg 2017;44:477-81.
15. Chang CM, Edwards SH, Arab A, et al. Biomarkers of tobacco exposure: summary of an FDA-Sponsored public workshop. Cancer Epidemiol Biomarkers Prev 2017;26:291-302.
16. Shahab L, Goniewicz ML, Blount BC, et al. Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users. Ann Intern Med 2017;166:390.
17. Goniewicz ML, Smith DM, Edwards KC, et al. Comparison of nicotine and toxicant exposure in users of electronic cigarettes and Combustible cigarettes: findings from the population assessment of tobacco and health study. JAMA Network OpenIn press.
18. Gaur S, Agnihotri R. Health effects of trace metals in electronic cigarette Aerosols-a systematic review. Biol Trace Elem Res 2018:1-21.
19. Chen CL, Whanger PD. Interaction of selenium and arsenic with metallothionein: effect of vitamin B12. J Inorg Biochem 1994;54:267-76.
20. Nielson KB, Atkin CL, Winge DR. Distinct metal-binding configurations in metallothionein. J Biol Chem 1985;260:5342-50.
21. Kimura S, Yamauchi H, Hibino Y, et al. Evaluation of urinary 8-hydroxydeoxyguanine in healthy Japanese people. Basic Clin Pharmacol Toxicol 2006;98:496-502.
22. Mizushima Y, Kan S, Yoshida S, et al. Changes in urinary levels of 8-hydroxy-2'-deoxyguanosine due to aging and smoking. Geriatr Gerontol Int 2001;1:52-5.
23. Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J Lipid Res 2007;48:1607-17.
24. Swierzcek S, Abuknesha RA, Chivers I, et al. Enzyme-Immunoassay for the determination of metallothionein in human urine: application to environmental monitoring. Biomarkers 2004;9:331-40.
25. Ruttkay-Nedecky B, Nejdl L, Gumulec J, et al. The role of metallothionein in oxidative stress. Int J Mol Sci 2013;14:6044-66.
26. Valavanidis A, Vlachogianni T, Fiotakis K. Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other Respirable particles. Int J Environ Res Public Health 2009;6:445-62.
27. Kim J-Y, Lee J-W, Youn Y-J, et al. Urinary levels of 8-iso-prostaglandin F2and 8-Hydroxydeoxyguanine as markers of oxidative stress in patients with coronary artery disease. Korean Circ J 2012;42:614-7.
28. Bernhard D, Rossmann A, Wick G. Metals in cigarette smoke. IUBMB Life 2005;57:805-9.
29. Wei B, Feng J, Rehmani IJ, et al. A high-throughput robotic sample preparation system and HPLC-MS/MS for measuring urinary anatabine, anabasine, nicotine and major nicotine metabolites. Clinica Chimica Acta 2014;436:290-7.
30. Xia B, Xia Y, Wong J, et al. Quantitative analysis of five tobacco-specific N-nitrosamines in urine by liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. Biomed Chromatogr 2014;28:375-84.
31. Morita H, Ikeda H, Haramaki N, et al. Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term smokers. J Am Coll Cardiol 2005;45:589-94.
32. Goel R, Bitzer Z, Reilly SM, et al. Variation in free radical yields from U. S. marketed cigarettes. Chem Res Toxicol 2017;30:1038-45.
33. Olmedo P, Goessler W, Tanda S, et al. Metal concentrations in e-cigarette liquid and aerosol samples: the contribution of metallic coils. Environ Health Perspect 2018;126:027010.
34. Mocchegiani E, Malavolta M, Muti E, et al. Zinc, metallothioneins and longevity: interrelationships with niacin and selenium. Current Pharmaceutical Design 2008;14:2719-32.
35. Pappas RS, Fresquez MR, Martone N, et al. Toxic metal concentrations in mainstream smoke from cigarettes available in the USA. J Anal Toxicol 2014;38:204-11.
36. Abd El-Samad M, Hanafi HA. Analysis of toxic heavy metals in cigarettes by instrumental neutron activation analysis. Journal Taibah Uni Sci 2017;11:822-9.
37. Ercal N, Gurer-Orhan H, Aykin-Burns N. Toxic metals and oxidative stress Part I: mechanisms involved in metal-induced oxidative damage. Curr Top Med Chem 2001;1:529-39.
38. Valko M, Morris H, Cronin MTD. Metals, toxicity and oxidative stress. Curr Med Chem 2005;12:1161-208.
39. Milne GL, Yin H, Hardy KD, et al. Isoprostane generation and function. Chem Rev 2011;111:5973-96.
40. McCord MC, Aizenman E. The role of intracellular zinc release in aging, oxidative stress, and Alzheimer's disease. Front Aging Neurosci 2014;6.
41. Vinceti M, Wei ET, Malagoli C, et al. Adverse health effects of selenium in humans. Rev Environ Health 2001;16:233-51.
42. Ogura S, Shimosawa T. Oxidative stress and organ damages. Curr Hypertens Rep 2014;16.
43. Rahman T, Hosen I, Islam MMT, et al. Oxidative stress and human health. Advanc Biosci Biotechnol 2012;03:997-1019.
44. MacFarquhar JK, Broussard DL, Melstrom P, et al. Acute selenium toxicity associated with a dietary supplement. Arch Intern Med 2010;170:256.
45. See KA, Lavercombe PS, Dillon J, et al. Accidental death from acute selenium poisoning. Med J Aust 2006;185:388-9.
46. Rayman MP. Selenium and human health. The Lancet 2012;379:1256-68.
47. Fosmire GJ. Zinc toxicity. Am J Clin Nutr 1990;51:225-7.
48. Nriagu J. Zinc toxicity in humans. Encyclopedia of Environmental Health 2011:801-7.
49. Eckschlager T, Adam V, Hrabeta J, et al. Metallothioneins and cancer. Current Protein2009;10:360-75.
50. Zhou G, Li X, Hein DW, et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol 2008;52:655-66.
51. Klaassen CD, Liu J, Diwan BA. Metallothionein protection of cadmium toxicity. Toxicol Appl Pharmacol 2009;238:215-20.
52. Kroese LJ, Scheffer PG. 8-Hydroxy-2'-Deoxyguanosine and cardiovascular disease: a systematic review. Curr Atheroscler Rep 2014;16:452.
53. Kim GH, Kim JE, Rhie SJ, et al. The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol 2015;24:325.
54. Vassalle C, Petrozzi L, Botto N, et al. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004;256:308-15.
55. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25:279-86.
56. Montuschi P, Ciabattoni G, Paredi P, et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998;158:1524-7.
57. Stathopoulos D, Loukides S, Syrigos K. 8-Isoprostane in exhaled breath condensate of patients with non-small cell lung cancer: the effect of chemotherapy. Anticancer Res 2014;34:5143-5.
58. Rossner P, Gammon MD, Terry MB, et al. Relationship between urinary 15-F2t-isoprostane and 8-oxodeoxyguanosine levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:639-44.